173 related articles for article (PubMed ID: 29146652)
1. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis.
Choi SE; Brandeau ML; Basu S
BMJ Open; 2017 Nov; 7(11):e018374. PubMed ID: 29146652
[TBL] [Abstract][Full Text] [Related]
2. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
4. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
5. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
7. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Intensive Blood Pressure Management.
Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
[TBL] [Abstract][Full Text] [Related]
10. Screening for proteinuria in US adults: a cost-effectiveness analysis.
Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR
JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of renin-guided treatment of hypertension.
Smith SM; Campbell JD
Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
[TBL] [Abstract][Full Text] [Related]
15. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
Nordmann AJ; Krahn M; Logan AG; Naglie G; Detsky AS
Pharmacoeconomics; 2003; 21(8):573-85. PubMed ID: 12751915
[TBL] [Abstract][Full Text] [Related]
16. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
van Gestel A; Schouten JS; Beckers HJ; Severens JL; Hendrikse F; Webers CA
Acta Ophthalmol; 2014 Sep; 92(6):513-23. PubMed ID: 24330516
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of guidelines for antihypertensive care in Finland.
Booth N; Jula A; Aronen P; Kaila M; Klaukka T; Kukkonen-Harjula K; Reunanen A; Rissanen P; Sintonen H; Mäkelä M
BMC Health Serv Res; 2007 Oct; 7():172. PubMed ID: 17958883
[TBL] [Abstract][Full Text] [Related]
18. [Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S39-42. PubMed ID: 21839897
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
Hogan TJ; Elliott WJ; Seto AH; Bakris GL
Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
